J-W Bai1, H-Z Xue, C Zhang. 1. Department of Gastrointestinal Surgery, People's Hospital of Zhengzhou University, Zhengzhou, China. xue_huanzhou@sina.com.
Abstract
OBJECTIVE: Colorectal cancer (CRC) is one of the most prevalent carcinomas worldwide. Tumor metastasis and recurrence are leading causes of CRC-related deaths. Given the role of microRNA (miRNA) in CRC invasion and metastasis, we explored the association between miRNA-143 expression and clinicopathologic characteristics in CRC, as well as the effects of miRNA-143 on CRC cell invasion in vitro. MATERIALS AND METHODS: Quantitative real-time PCR was conducted to assess the expression of miR-143 in tissue specimens and cell lines. CCK-8 test and transwell assay were conducted to explore the effects of miR-143 on the proliferation and invasion of CRC cell lines, respectively. Luciferase reporter assay and transfection technique were used to validate the correlation between miR-143 and epidermal growth factor receptor 3 (ERBB3) in CRC. RESULTS: miR-143 was down-regulated in human CRC tissues, its expression negatively correlated with CRC metastasis. miR-143 negatively regulated ERBB3 expression by directly targeting its 3'UTR in human colorectal cancer cells. Overexpression of miR-143 inhibited CRC cells invasion but did not affect its proliferation in vitro. Knockdown of ERBB3 also significantly suppressed CRC cells invasion. CONCLUSIONS: These data suggest that miR-143 suppressed the invasion and metastasis ability by suppressing ERBB3 expression in CRC cells, providing a novel and promising therapeutic target for the prevention and treatment of CRC.
OBJECTIVE:Colorectal cancer (CRC) is one of the most prevalent carcinomas worldwide. Tumor metastasis and recurrence are leading causes of CRC-related deaths. Given the role of microRNA (miRNA) in CRC invasion and metastasis, we explored the association between miRNA-143 expression and clinicopathologic characteristics in CRC, as well as the effects of miRNA-143 on CRC cell invasion in vitro. MATERIALS AND METHODS: Quantitative real-time PCR was conducted to assess the expression of miR-143 in tissue specimens and cell lines. CCK-8 test and transwell assay were conducted to explore the effects of miR-143 on the proliferation and invasion of CRC cell lines, respectively. Luciferase reporter assay and transfection technique were used to validate the correlation between miR-143 and epidermal growth factor receptor 3 (ERBB3) in CRC. RESULTS:miR-143 was down-regulated in human CRC tissues, its expression negatively correlated with CRC metastasis. miR-143 negatively regulated ERBB3 expression by directly targeting its 3'UTR in humancolorectal cancer cells. Overexpression of miR-143 inhibited CRC cells invasion but did not affect its proliferation in vitro. Knockdown of ERBB3 also significantly suppressed CRC cells invasion. CONCLUSIONS: These data suggest that miR-143 suppressed the invasion and metastasis ability by suppressing ERBB3 expression in CRC cells, providing a novel and promising therapeutic target for the prevention and treatment of CRC.
Authors: Jeffrey S Ross; Marwan Fakih; Siraj M Ali; Julia A Elvin; Alexa B Schrock; James Suh; Jo-Anne Vergilio; Shakti Ramkissoon; Eric Severson; Sugganth Daniel; David Fabrizio; Garrett Frampton; James Sun; Vincent A Miller; Philip J Stephens; Laurie M Gay Journal: Cancer Date: 2018-01-16 Impact factor: 6.860
Authors: Alicia Romero-Lorca; Apolonia Novillo; María Gaibar; María Fuencisla Gilsanz; Miguel Galán; Laura Beltrán; Beatriz Antón; Diego Malón; Amalia Moreno; Ana Fernández-Santander Journal: Pharmgenomics Pers Med Date: 2021-09-29
Authors: Mohd O F Sikder; Sathish Sivaprakasam; Timothy P Brown; Muthusamy Thangaraju; Yangzom D Bhutia; Vadivel Ganapathy Journal: Biochem J Date: 2020-04-30 Impact factor: 3.857
Authors: Valeria Tubita; Joan Segui-Barber; Juan José Lozano; Elisenda Banon-Maneus; Jordi Rovira; David Cucchiari; Daniel Moya-Rull; Federico Oppenheimer; Hernando Del Portillo; Josep M Campistol; Fritz Diekmann; Maria José Ramirez-Bajo; Ignacio Revuelta Journal: Sci Rep Date: 2019-08-01 Impact factor: 4.379